RE:RE:How could Mackie have sold this to their clientsI agree that the upside remains huge but the debacle of this offering, with new pieces of it showing up most every day, cannot be overlooked. But I may take a longer break than Scarlett did, so you may get a break from my righteous indignation (which you refer to as whining).
jfm1330 wrote: Skipping a lot of posts here since it is very hard to read. It's a whinning festival with no end. That being said SPCEO, if you put 75% chance of success in NASH and apply the Mackie analyst numbers to it what would be the share price? And if you are confident in oncology, how much do you add to that???
What I am trying to say is what is the potential for the SP of Thera in the next five years, even with 120 M shares outstanding? 20$ US? 40$ US? 60$ US.
What I am trying to say, is that despite all the frustration you can have with the last financing, with the analysts, with the market, with the management. The fact is that the potential is still huge and the day they will come with real positive data on humans, if it happens, the SP will be overvalued at some point. If NASH and oncology end up being real success, this recent dilution will not mean much. The key is still the success of these two programs an decisions they will make if success is there. In other words, the dilution can be a step back two make a leap forward. I think you are forgetting the big picture out of frustration. Thera is still early in the game with NASH and oncology. There will be opportunities to make up in term of value for shareholders if these two programs are successful.
SPCEO1 wrote: if they really only believe there is a 10% chance of success in NASH?
None of this adds up. The foolishness of it all is hard to take on all fronts.